---
title: "CASI Pharmaceuticals Receives Drug Registration Certificate for Thiotepa in China"
description: "CASI Pharmaceuticals Inc. has received a Drug Registration Certificate for Thiotepa for Injection in China, valid until February 1, 2031. The company holds exclusive distribution rights from ESTEVE Ph"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275471513.md"
published_at: "2026-02-10T14:01:05.000Z"
---

# CASI Pharmaceuticals Receives Drug Registration Certificate for Thiotepa in China

> CASI Pharmaceuticals Inc. has received a Drug Registration Certificate for Thiotepa for Injection in China, valid until February 1, 2031. The company holds exclusive distribution rights from ESTEVE Pharmaceuticals GmbH. CASI plans to transfer all rights related to Thiotepa in China, excluding Hong Kong, Macau, and Taiwan, to Kaixin Pharmaceuticals Inc.

CASI Pharmaceuticals Inc. announced that its subsidiary, CASI Pharmaceuticals (China) Co., Ltd., has received a Drug Registration Certificate from the National Medical Products Administration for Thiotepa for Injection in China. The certificate is valid until February 1, 2031. CASI holds exclusive distribution rights for Thiotepa in China from ESTEVE Pharmaceuticals GmbH. The company has previously disclosed plans to dispose of all rights related to Thiotepa in China (excluding Hong Kong, Macau, and Taiwan) and certain other pipeline products to Kaixin Pharmaceuticals Inc. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-012391), on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [KXIN.US - Kaixin](https://longbridge.com/en/quote/KXIN.US.md)
- [CASI.US - CASI Pharmaceuticals](https://longbridge.com/en/quote/CASI.US.md)
- [CASIF.US - CASI PHARMACEUTICALS INC](https://longbridge.com/en/quote/CASIF.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CASI Pharmaceuticals Closes Second Tranche of US$20 Million Convertible Note Financing | CASI Pharmaceuticals has closed the second tranche of its US$20 million convertible note financing, issuing a new US$5 m | [Link](https://longbridge.com/en/news/272431475.md) |
| What Drove CASI Pharmaceuticals' 24% Rise After Hours? | CASI Pharmaceuticals Inc. saw a 24.48% rise in after-hours trading to $0.25 following its announcement to transition to  | [Link](https://longbridge.com/en/news/277005912.md) |
| Glenmark Pharmaceuticals Unit to Launch Sodium Phosphates Injection | Glenmark Pharmaceuticals Unit to Launch Sodium Phosphates Injection | [Link](https://longbridge.com/en/news/277144458.md) |
| Deep Dive Into Collegium Pharmaceutical Stock: Analyst Perspectives (5 Ratings) | In the last three months, five analysts have rated Collegium Pharmaceutical (NASDAQ:COLL), showing a mix of bullish to b | [Link](https://longbridge.com/en/news/277089765.md) |
| CASI Pharmaceuticals Closes First US$5 Million Tranche of Convertible Note Financing | CASI Pharmaceuticals has closed the first tranche of a US$20 million convertible note financing, issuing a US$5 million  | [Link](https://longbridge.com/en/news/271208648.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.